With improvements in therapy for inflammatory bowel disease (IBD) and changes in the prevalence of obesity, the phenotype of Crohn's Disease (CD) is changing. These changes may herald an increase in the incidence of non-alcoholic fatty liver disease (NAFLD) in this population